A vaccine derived from the same protamine-formulated mRNA platform encoding five tumor-associated antigens (NY-ESO-1, MAGE-C1, MAGE-C2, survivin and trophoblast glycoprotein (TPBG)) was further evaluated in a phase I/IIa dose-escalation trial in seven patients with locally advanced and 39 patients with metastatic non-small-cell lung cancer (NSCLC) and controlled disease after first-line therapy (NCT00923312) [100]. This evidence concerns the gene TPBG and non-small cell lung carcinoma.